Blue Earth promotes results for PET/CT agent
Blue Earth said PET/CT with Axumin revealed one or more sites of disease recurrence in men with biochemically recurrent prostate cancer. Also, based on the pattern of recurrence, the intervention resulted in a change in management in 59% of the patients. {read more here}
A team of German researchers used PET/CT and modeling practices to create a new method to model and predict tumor response in radioligand therapy (RLT), which authors say is the first attempt to do so. The study was published May 10 in the Journal of Nuclear Medicine. {read more here}
A prospective comparison study of two PET tracers found 18F-FDG could provide valuable measures of activity in bone-dominant (BD) metastatic breast cancer (MBC) patients, while also predicting responses to therapy. {read more here}
Interim positron-emission tomography (PET) may predict survival, but intensifying treatment based on PET may not improve therapeutic outcomes among patients with aggressive non-Hodgkin lymphoma (NHL), according to a study published in the Journal of Clinical Oncology.1 {read more here}